Quarterly Result5 Nov 2025, 08:04 pm
Aurobindo Pharma Reports Q2 and H1 Results for FY2025-2026
AI Summary
Aurobindo Pharma Ltd. has announced its standalone and consolidated unaudited financial results for the second quarter and half year ended September 30, 2025. The total revenue from operations stands at INR 29,492.4 million for Q2 and INR 58,811.8 million for H1. The profit before tax is INR 7,500.9 million for Q2 and INR 15,053.7 million for H1. The profit after tax is INR 11,405.0 million for Q2 and INR 8,665.7 million for H1. The total comprehensive income for H1 is INR 10,257.0 million.
Key Highlights
- Total revenue from operations for Q2 is INR 29,492.4 million.
- Profit before tax for Q2 is INR 7,500.9 million.
- Profit after tax for Q2 is INR 11,405.0 million.
- Total revenue from operations for H1 is INR 58,811.8 million.
- Total comprehensive income for H1 is INR 10,257.0 million.